Atlas Trials

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

Clinical trial NCT04597125 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04597125
Sponsor
Bayer
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Start date
2020-11-09
Primary completion
2025-11-21
Enrollment
654

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.